GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
GeneDx (WGS) PT Raised to $45 at BTIG
July 31, 2024 4:57 AM EDTBTIG analyst Mark Massaro raised the price target on GeneDx (NASDAQ: WGS) to $45.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "Shares of WGS are indicating up +10% AH following another strong quarterly beat-and-raise. WGS drove a ~$10M revenue beat (~16%... More
